Skip to main content
. Author manuscript; available in PMC: 2015 Apr 25.
Published in final edited form as: Mol Cell Endocrinol. 2014 Mar 1;387(0):52–58. doi: 10.1016/j.mce.2014.01.024

Figure 2. Effectiveness of GPR30-AS knockdown of GPR30 immunoprotein levels in the hippocampal CA1 region of E2-BSA treated rats.

Figure 2

(A) Ovariectomized rats were pretreated with E2-BSA, E2-BSA plus GPR30-AS, or E2-BSA plus GPR30-MS and subjected to ischemic reperfusion for 10 min following GCI. Western blot analyses of total GPR30 expression and β-Actin were performed with hippocampal CA1 protein in the indicated groups of ovariectomized rats. #P <0.05 versus GPR30-MS group or E2-BSA group. Data are mean ± SD from four different animals. (B) GPR30 immunoreactivity was detected by immunohistochemical staining in hippocampal CA1 region. Magnification, 40×; Scale bar, 25μm. n=4.